Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide

@article{Lin2005AntistaphylococcalAO,
  title={Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide},
  author={Gengrong Lin and Kim L. Credito and Lois M. Ednie and Peter C. Appelbaum},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2005},
  volume={49},
  pages={770 - 772}
}
ABSTRACT Dalbavancin, tested against 146 staphylococci, was more potent than other drugs tested, with an MIC at which 50% of staphylococci were inhibited of 0.03 μg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 μg/ml by microdilution. For all strains, MICs of vancomycin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin were ≤4.0 μg/ml. Dalbavancin was bactericidal at four times the MIC against all six strains tested. 
Antipneumococcal Activity of Dalbavancin Compared to Other Agents
TLDR
Against 307 pneumococci of various resistotypes, dalbavancin MICs were 0.008 to 0.125 μg/ml, and vancomycin and teicoplanin killed 10 and 8 strains, respectively, at 2× MIC after 24 h. Expand
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions.
TLDR
Dalbavancin was synergistic or partially synergistic with oxacillin for staphylococci, including methicillin-resistant strains, vancomycin-intermediate Staphyl bacteria, a significant finding that warrants further investigation to establish its potential clinical relevance. Expand
Original Contribution IN VITRO ACTIVITY OF LEVOFLOXACIN, GEMIFLOXACIN, LINEZOLID, VANCOMYCIN, DALBAVANCIN AND TELAVANCIN AGAINST GRAM-POSITIVE STRAINS, ISOLATED FROM CLINICAL SAMPLES
TLDR
Gemifloxacin could be used with success for staphylococcal / MRSA / strains treatment and linezolid, dalbavancein and telavancin were active against all the strains tested, with low MIC’s levels. Expand
In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections
TLDR
Tests of dalbavancin's in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC90 of ≤0.125 μg/ml, compared to respective MIC90s for MSSA and MRSA. Expand
Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Among 10 hospital- and community-acquired Staphylococcus aureus strains with differing methicillin and vancomycin resistotypes, all strains were susceptible to ceftobiprole at MICs <or=2.0 microg/mL,Expand
Bactericidal Activity and Resistance Development Profiling of Dalbavancin
TLDR
It is suggested that dalbavancin will be an effective choice for the management of patients with SSSIs because of its half-life of 5 to 7 days in humans and its promise for a convenient weekly dosing regimen. Expand
Oritavancin: a new avenue for resistant Gram-positive bacteria
Oritavancin, a new semisynthetic glycopeptide has a spectrum of activity similar to vancomycin, although it exhibits potent antimicrobial activity against vancomycin-resistant staphylococci andExpand
Review of dalbavancin, a novel semisynthetic lipoglycopeptide
TLDR
Dalbavancin is a semisynthetic lipoglycopeptide that is derived from teicoplanin with an extended half-life that enables once-weekly dosing that may serve as an appealing alternative agent in the treatment of Gram-positive infections, especially with its convenient once- weekly regimen. Expand
Dalbavancin: a novel antimicrobial
TLDR
A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1–2 doses of dalbavancin vs. linezolid demonstrated non‐inferiority and a comparable safety profile. Expand
Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
TLDR
Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents
TLDR
Ranbezolid was bacteriostatic against pneumococci and Vancomycin and quinupristin-dalfopristin were also very active, and ranbeZolid MICs for coagulase-negative staphylococci were lower than those for Staphylitis aureus. Expand
Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.
TLDR
A spectrum of pneumococci with varying susceptibilities to beta-lactams, macrolides and quinolones was tested for susceptibility to nine antibiotics, including the novel lipopeptide daptomycin, which demonstrated bactericidal activity in seven of eight strains tested. Expand
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
TLDR
Dalbavancin activity indicates that the new glycopeptide has significant activity, superior to available agents in the class, and a potency that was uniform across geographically sampled organisms. Expand
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria
TLDR
Dalbavancin exhibited excellent activity against gram-positive strains tested and warrants clinical evaluation, 1 to 3 dilutions more active than vancomycin against most strains. Expand
Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin
TLDR
Dalbavancin given once daily or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life. Expand
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.
The in vitro activity of the oxazolidinone linezolid was compared with the activities of vancomycin and teicoplanin against 450 Gram-positive clinical isolates, including a variety of multiplyExpand
In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci
ABSTRACT Of 94 clinical isolates of Staphylococcus aureus(n = 51) and coagulase-negative staphylococci (CNS) (n = 43), mutations in the quinolone resistance-determining region of topoisomerases GrlA,Expand
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology
TLDR
Of the new compounds tested, RP 59500 and sparfloxacin show promise for the treatment of infections caused by penicillin-susceptible and -resistant pneumococci, and at a concentration equal to the MIC it was bactericidal within 3 h. Expand
In Vitro Evaluation of BI 397, a Novel Glycopeptide Antimicrobial Agent
TLDR
Animal pharmacokinetic data published elsewhere suggest that BI 397 may be dosed less frequently than teicoplanin and the results of early studies in humans are awaited with interest, especially when treating teicsoplanin-refracto-ry coagulase-negative staphylococci. Expand
Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
TLDR
It is demonstrated that only a limited number of classical mutations in grlA and gyrA contributed to resistance in clinical isolates of S. aureus, and sitafloxacin and clinafloxacins are two very promising new FQs with good anti-staphylococcal activity. Expand
...
1
2
3
...